This study will prospectively monitor cancer patients receiving chemotherapy (including molecular targeted therapies) for cardiovascular adverse events using biomarkers and imaging. The goal is to develop a predictive model for major adverse cardiovascular events (MACE) in this population by integrating both local factors (e.g. central venous catheter-related thrombosis) and systemic factors (e.g. age, comorbidities, genetic predisposition). An active surveillance system employing periodic cardiac evaluations (ECG, echocardiography) and biomarker measurements (troponin T, NT-proBNP) will enable early detection of cardiotoxic effects. The impact of these adverse events and the monitoring strategy on patients' quality of life will also be assessed.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1.Adults (age \> 18 years) with a pathologically confirmed malignant tumor (any type of cancer); 2.Currently receiving or planning to receive chemotherapy (including regimens containing molecular targeted drugs) as adjuvant treatment for cancer; 3.Willing and able to participate in the study with provision of informed consent, and agreeable to provide required clinical data and biological samples.
\-
Exclusion Criteria:
1. Incomplete basic patient information or medical records (missing key data necessary for the study);
2. Failure to complete the full course of planned chemotherapy at the study center (e.g., patient did not adhere to or finish all cycles of adjuvant chemotherapy at our institution);
3. History of severe acute cardiovascular or cerebrovascular events within 6 months prior to enrollment, including acute heart failure, acute myocardial infarction, acute intracerebral hemorrhage (stroke), malignant arrhythmia, or New York Heart Association (NYHA) Class IV/V heart failure;
4. Missing essential pre- or post-chemotherapy evaluations: patients who did not undergo complete baseline or end-of-treatment assessments (such as blood routine, hepatic/renal function, coagulation profile, cardiac enzymes (troponin T), NT-proBNP (or BNP), 12-lead ECG, and echocardiogram)
Primary outcome measure(s)
Incidence of New Onset Major Adverse Cardiovascular Events (MACE) by End of Chemotherapy — From initiation of chemotherapy to end of adjuvant chemotherapy (approximately up to 6 months per patient). Occurrence of any new cardiovascular adverse event from start of chemotherapy to the completion of the chemotherapy regimen. "MACE" is defined per ESC guidelines to include major cardiac events such as new myocardial dysfunction, symptomatic heart failure, coronary artery disease (e.g. myocardial infarction), clinically significant valvular disease, arrhythmia (e.g. atrial fibrillation), new or worsening hypertension, thromboembolic events (including deep vein thrombosis or pulmonary embolism), peripheral vascular disease, pulmonary hypertension, or pericardial disease. Any such event recorded on electrocardiogram, cardiac ultrasound (echocardiography), or via cardiac enzymes (troponin T) and biomarkers (NT-proBNP/BNP) by the end of the adjuvant chemotherapy cycle, relative to the patient's pre-treatment baseline, will be counted as an outcome event. (Early cardiovascular events are defined as those occurring during the chemotherapy period.)
Trial sites (1)
Facility
City
Region
Status
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou
Guangdong
Recruiting
More Sixth Affiliated Hospital, Sun Yat-sen University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.